Table 1 Clinicopathologic characteristics of patients with ALM and non-ALM classified into T1, T1a, and T1b groups.
From: Prognostic significance of acral lentiginous histologic type in T1 melanoma
T1 | T1a | T1b | ||||
---|---|---|---|---|---|---|
Characteristic | ALM (N = 129) | Non-ALMa (N = 699) | ALM (N = 82) | Non-ALMa (N = 454) | ALM (N = 47) | Non-ALMa (N = 245) |
Sex, n (%) | ||||||
Male | 42 (33) | 355 (51)b | 27 (33) | 221 (49)c | 15 (32) | 134 (55)c |
Female | 87 (67) | 344 (49) | 55 (67) | 233 (51) | 32 (68) | 111 (45) |
Age, years | ||||||
Median (range) | 56.1 (9.8–99.4) | 50.7 (2.3–7.7)c | 55.7 (9.8–99.4) | 49.1 (2.3–86.4)c | 56.7 (21.3–85.4) | 52.6 (15.8–87.7)c |
Race/ethnicity, n (%) | ||||||
Caucasian | 95 (78) | 677 (97)b | 59 (77) | 439 (97)b | 36 (80) | 238 (97)b |
Hispanic | 18 (15) | 15 (2) | 12 (16) | 10 (2) | 6 (13) | 5 (2) |
Other | 9 (7) | 6 (1) | 6 (8) | 4 (1) | 3 (7) | 2 (1) |
Unknown | 7 | 1 | 5 | 1 | 2 | 0 |
Histologic subtype, n (%) | ||||||
ALM | 129 (100) | 82 (100) | 47 (100) | |||
SMM | 617 (88)c | 402 (89)c | 215 (88)c | |||
LMM | 60 (9) | 43 (9) | 17 (7) | |||
NM | 22 (3) | 9 (2) | 13 (5) | |||
Clark level, n (%) | ||||||
II | 57 (45) | 174 (25)b | 49 (60) | 154 (34)b | 8 (17) | 20 (8)c |
III | 37 (29) | 369 (53) | 24 (29) | 233 (52) | 13 (28) | 136 (56) |
IV | 34 (27) | 153 (22) | 9 (11) | 65 (14) | 25 (54) | 88 (36) |
V | 0 | 1 (<1) | 0 | 0 | 0 | 1 (<1) |
Unknown | 1 | 2 | 0 | 2 | 1 | 0 |
Breslow thickness, mm | ||||||
Median (range) | 0.7 (0.2–1.0) | 0.7 (0.1–1.0) | 0.5 (0.2–0.8) | 0.6 (0.1–0.8) | 0.9 (0.5–1.0) | 0.9 (0.3–1.0) |
Mitosis, n (%) | ||||||
<1/mm2 | 69 (68) | 414 (63) | 50 (82) | 309 (7) | 19 (48) | 105 (45) |
≥1/mm2 | 32 (32) | 246 (37) | 11 (18) | 118 (28) | 21 (53) | 128 (55) |
Unknown | 28 | 39 | 21 | 27 | 7 | 12 |
Median (range) | 0 (0–9) | 0 (0–20) | 0 (0–4) | 0 (0–5) | 1.0 (0–9.0) | 1.0 (0–20.0) |
Ulceration, n (%) | ||||||
Absent | 121 (95) | 677 (97) | 82 (100) | 454 (100) | 40 (85) | 224 (91) |
Present | 7 (5) | 21 (3) | 0 | 0 | 7 (15) | 21 (9) |
Breslow thickness <0.8 mm, n (%) | 3 (6) | 10 (4) | ||||
Breslow thickness ≥0.8 mm, n (%) | 4 (9) | 11 (5) | ||||
Unknown | 1 | 1 | 0 | 0 | 0 | 0 |
Lymphovascular invasion, n (%) | ||||||
Absent | 127 (98) | 670 (99) | 82 (100) | 437 (99) | 45 (96) | 233 (99) |
Present | 2 (2) | 5 (1) | 0 | 3 (1) | 2 (4) | 2 (1) |
Unknown | 0 | 24 | 0 | 14 | 0 | 10 |
Perineural invasion, n (%) | ||||||
Absent | 127 (98) | 675 (100) | 82 (100) | 440 (100) | 45 (96) | 235 (100)c |
Present | 2 (2) | 0 | 0) | 0 | 2 (4) | 0 |
Unknown | 0 | 24 | 0 | 14 | 0 | 10 |
Regression, n (%) | ||||||
Absent | 101 (80) | 463 (70)c | 65 (79)c | 288 (66)c | 36 (80) | 175 (77)c |
Present | 26 (20) | 200 (30) | 17 (2) | 148 (34) | 9 (20) | 52 (23) |
Unknown | 2 | 36 | 1 | 18 | 2 | 18 |
Tumor-infiltrating lymphocytes, n (%) | ||||||
Non-brisk/minimal | 119 (98) | 566 (86)b | 79 (98) | 374 (87)c | 40 (100) | 192 (85)c |
Brisk | 2 (2) | 89 (14) | 2 (2) | 55 (13) | 0 | 34 (15) |
Unknown | 8 | 44 | 1 | 25 | 7 | 19 |
Vertical growth phase, n (%) | ||||||
Absent | 60 (50) | 116 (18)b | 53 (66) | 104 (24)b | 7 (17) | 12 (5)c |
Present | 61 (50) | 538 (82) | 27 (34) | 321 (76) | 34 (83) | 217 (95) |
Unknown | 8 | 45 | 2 | 29 | 6 | 16 |
Microsatellitosis, n (%) | ||||||
Absent | 129 (100) | 672 (99) | 82 (100) | 438 (100) | 47 (100) | 234 (99) |
Present | 0 | 4 (1) | 0 | 2 (<1) | 0 | 2 (1) |
Unknown | 0 | 23 | 0 | 14 | 0 | 9 |
Predominant cytology, n (%) | ||||||
Epithelioid | 88 (70) | 392 (93)b | 63 (77) | 274 (94)b | 25 (58) | 118 (91)b |
Spindle | 9 (7) | 18 (4) | 3 (4) | 11 (4) | 6 (14) | 7 (5) |
Nevoid | 28 (22) | 10 (2) | 16 (20) | 5 (2) | 12 (28) | 5 (4) |
Unknown | 4 | 279 | 0 | 164 | 4 | 115 |
Sentinel lymph nodes, n (%) | ||||||
Negative | 64 (83) | 670 (96)b | 36 (88) | 444 (98)c | 28 (78) | 226 (92)c |
Positive | 13 (17) | 29 (4) | 5 (12) | 10 (2) | 8 (22) | 19 (8) |
Unknown | 52 | 0 | 48 | 0 | 11 | 0 |
Number of positive SLNs | ||||||
N | 13 | 29 | 5 | 10 | 8 | 19 |
Median (range) | 1 (1–4) | 1 (1–2) | 1.0 (1.0–1.0) | 1.0 (1.0–2.0) | 1.0 (1.0–4.0) | 1.0 (1.0–2.0) |
Non-sentinel lymph nodes, n (%) | ||||||
Negative | 12 (60) | 127 (99)b | 5 (50) | 85 (100)b | 7 (70) | 42 (98)c |
Positive | 8 (40) | 1 (1) | 5 (50) | 0 | 3 (30) | 1 (2) |
Unknown | 109 | 571 | 72 | 369 | 37 | 202 |
Number of positive non-SLNs | ||||||
n | 8 | 1 | 5 | 0 | 3 | 1 |
Median (range) | 3 (1–10) | 4 (4–4) | 3.0 (1.0–4.0) | – | 7.0 (1.0–10.0) | 4.0 (4.0–4.0) |
Local recurrence, n (%) | ||||||
No | 105 (94) | 697 (100)b | 67 (96) | 452 (100)c | 38 (90) | 245 (100)b |
Yes | 7 (6) | 2 (<1) | 3 (4) | 2 (<1) | 4 (10) | 0 |
Unknown | 17 | 0 | 12 | 0 | 5 | 0 |
Distant metastases, n (%) | ||||||
No | 117 (91) | 687 (98)b | 77 (94) | 449 (99)c | 40 (85) | 238 (97)c |
Yes | 12 (9) | 12 (2) | 5 (6) | 5 (1) | 7 (15) | 7 (3) |
Systemic therapy, n (%) | ||||||
No | 119 (92) | 688 (98) | 77 (94) | 451 (99) | 42 (89) | 237 (97) |
Yes | 10 (8) | 11 (2) | 5 (6) | 3 (1) | 5 (11) | 8 (3) |